Cardiovascular Disease Cholesterol Coronary Artery Disease 
Dr. Paddy Barrett
APRIL 4, 2025
When it comes to a proper ‘explanation’ of cardiovascular disease or a ‘plan’ to address it, you will have to learn or address a lot of this on your own. Some doctors are less interested in cardiovascular disease; their particular interest may be in another area, e.g., migraines or gastrointestinal health.
Dr. Paddy Barrett
FEBRUARY 27, 2024
mmol/l (130 mg/dl) or below, between 20-50% will already have coronary artery disease. As HBA1c increases, even in the normal range, the probability of coronary artery disease increases. Subscribe now 1 Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular Events.
Frontiers in Cardiovascular Medicine
JULY 31, 2024
Recent clinical trials demonstrated that proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors reduce cardiovascular events without affecting systemic inflammation in the patients with coronary artery disease, as determined by high sensitivity C-reactive protein (CRP) levels.
Physiologically Speaking
JANUARY 5, 2024
Exercise prevents and reverses cardiovascular disease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovascular disease (CVD) prevention and reversal. HbA1c also didn’t change.
Frontiers in Cardiovascular Medicine
JANUARY 21, 2024
Background and aims Epidemiology of atherosclerotic cardiovascular disease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL). The median duration of follow-up was 10 years (IQR 3–16). 3.17, P = 0.006).
Frontiers in Cardiovascular Medicine
MARCH 4, 2024
Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide. For many disease areas, nearly a half of drugs are approved by the U.S. Food & Drug Administration based on beneficial effects on surrogate endpoints.
Dr. Paddy Barrett
AUGUST 22, 2023
However Most people do not appreciate that being a carrier of APOE4 significantly increases the risk of cardiovascular disease also. APO E is also centrally involved in cholesterol metabolism. APO E is also centrally involved in cholesterol metabolism. i.e. LDL-Cholesterol/APOB goes down. Here’s how.
Expert insights. Personalized for you.
95 
Let's personalize your content